Takeda Pharmaceutical (TAK) Cash from Financing Activities (2018 - 2026)

Takeda Pharmaceutical's Cash from Financing Activities history runs 9 years deep, the most recent figure standing at -$494.1 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 75.02% year-over-year to -$494.1 million; the TTM figure through Mar 2026 stood at -$3.3 billion (up 33.75% YoY), while the FY2026 annual figure was -$3.3 billion, up 33.09% from the prior year.
• Cash from Financing Activities was -$494.1 million for Q1 2026 at Takeda Pharmaceutical, up from -$1.3 billion in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $2.0 billion in Q2 2024 to a low of -$4.3 billion in Q4 2024.
• Historically, Cash from Financing Activities has averaged -$1.1 billion across 5 years, with a median of -$737.8 million in 2024.
• Biggest YoY gain for Cash from Financing Activities was 582.07% in 2024; the steepest drop was 687.4% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at -$3.1 billion in 2022, then surged by 78.52% to -$661.4 million in 2023, then sank by 552.41% to -$4.3 billion in 2024, then surged by 71.02% to -$1.3 billion in 2025, then surged by 60.49% to -$494.1 million in 2026.
• The last three Cash from Financing Activities figures came in at -$494.1 million (Q1 2026), -$1.3 billion (Q4 2025), and -$81.3 million (Q3 2025), per Business Quant data.